摘要
以分析齐拉西酮治疗精神分裂症的临床效果为目的。将近两年于我院进行治疗的120例精神分裂症患者依据治疗时间分为创新组与传统组,每组各60例患者。传统组用利培酮进行治疗,创新组用齐拉西酮进行治疗。治疗后,创新组患者的阴性症状评分、阳性症状评分、常规症状评分与治疗前相比变化更大。相比较而言,创新组的治疗效果更明显,差异具有统计学意义(P<0.05)。创新组的无效果人数为2例,对应效率为3.33%;传统组的无效果人数为14例,对应效率为23.33%,前后相比差异明显,具有统计学意义(P<0.05)。创新组患者治疗前后的平均减分率为(61.42±22.63)%,传统组患者治疗前后的平均减分率为(62.42±25.63)%,前后数据相比差异不大,不具有统计学意义(P>0.05)。创新组发生不良反应的总人数为6例,对应发生率为10.00%。传统组发生不良反应的总人数为15例,对应发生率为25.00%,前后相比差异明显,具有统计学意义(P<0.05)。齐拉西酮治疗精神分裂症的临床效果更为突出,既可以减少不良反应发生率,又能提升临床治疗效果,值得在临床上积极推广。
To analyze clinical effect of ziprasidone in the treatment of schizophrenia, 120 schizophrenic patients treated in our hospital in the past two years were divided into innovative group and traditional group according to the treatment time, 60 patients in each group. The traditional group was treated with risperidone, while innovative group was treated with ziprasidone. After treatment, the scores of negative symptoms, positive symptoms and routine symptoms in innovative group changed more than before. Comparatively speaking, the effect of innovation group is more obvious, and the difference is statistically significant (P<0.05). The number of ineffective people in innovation group was 2, corresponding efficiency was 3.33%;the number of ineffective people in traditional group was 14, corresponding efficiency was 23.33%. The difference between before and after was significant (P<0.05). The average score reduction rate of innovative group before and after treatment was (61.42±22.63)%, while that of the traditional group before and after treatment was (62.42±25.63)%. There was no significant difference between the data before and after treatment (P>0.05). The total number of adverse reactions occurred in innovation group was 6 cases, and the corresponding incidence was 10.00%. The total number of adverse reactions in the traditional group was 15 cases, and the corresponding incidence was 25.00%. There was significant difference between before and after treatment (P<0.05). Ziprasidone is more effective in the treatment of schizophrenia, which can not only reduce the incidence of adverse reactions, but also improve the clinical efficacy. It is worthy of active promotion in clinical practice.
作者
刘丽萍
LIU Li-ping(Harbin First Specialized Hospital, Harbin 150056, China)
出处
《黑龙江科学》
2019年第20期28-29,共2页
Heilongjiang Science
作者简介
刘丽萍(1985-),女,博士研究生,主治医师。
